Madrigal’s Revenue Is Up 71% as Rezdiffra Ramps – the Stock Is Already Near Its Highs

Madrigal Pharmaceuticals, Inc. (MDGL) trades at $546.66, near the top of its two-year range of $208.41 to $598.91. This Madrigal Pharmaceuticals stock analysis looks at a biotech in the early, capital-intensive stage of commercializing its lead drug, and asks whether the current share price already reflects the good news in the numbers.

What Is Happening With the Stock Price

At $546.66, MDGL sits in the upper end of its two-year range, not far below the $598.91 high and well above the $208.41 low. That positioning reflects strong investor enthusiasm for the company’s commercial-stage progress, but it also means the stock has already priced in a meaningful amount of good news, leaving less room for error if the growth trajectory disappoints.

Quality: Is This a Financially Sound Business?

Madrigal’s Quality profile is typical of a commercial-stage biotech still investing heavily in launch. Gross margin is exceptionally high at 91.5%, reflecting the economics of a specialty pharmaceutical product, but operating margin of -15.5% and net profit margin of -25.3% show the business is still spending well ahead of current revenue, with earnings per share of -$13.99 and return on equity of -53.3%. The balance sheet, however, is a genuine strength: a current ratio of 3.20 and quick ratio of 2.76 indicate ample liquidity, and free cash flow of -$80M is a modest burn relative to the company’s $12.63B market cap and manageable debt-to-equity of 0.66. This Madrigal Pharmaceuticals stock analysis views the cash burn as a function of commercial launch investment rather than balance-sheet distress.

Growth: Does This Company Have Real Upside?

Growth is Madrigal’s standout metric, and the scoring model reflects it with a Growth score of 98 out of 100. Trailing-twelve-month revenue growth of 71.2% points to a fast-scaling product launch; five-year revenue CAGR is not available (N/A), consistent with a company only recently transitioning from clinical-stage to commercial-stage. Earnings growth cannot be measured while the company remains unprofitable. EV/Revenue of 9.23 shows the market is paying up for that growth, a multiple that will need continued strong revenue expansion to look reasonable in hindsight.

Opportunity: Is Now a Good Time to Enter?

The Opportunity score of just 7 out of 100 is the clearest caution flag here. There is no P/E ratio given the absence of GAAP earnings, and price-to-book of 24.11 is a steep multiple by any conventional measure. Combined with a share price already near the top of its two-year range, the valuation leaves little margin of safety: an entry today is a bet that the revenue ramp not only continues but accelerates, since the current price does not appear to offer a discount against that outcome.

Madrigal Pharmaceuticals Stock Analysis: The Bottom Line

This Madrigal Pharmaceuticals stock analysis concludes with a Hold signal from the quantitative scoring model – a data-driven research starting point, not personalized advice to transact. The bull case is strong: 71.2% TTM revenue growth, a 91.5% gross margin, and a well-capitalized balance sheet with a 3.20 current ratio show a launch that is executing well and is not at near-term risk of running out of cash. The bear case centers on valuation and stage risk – the company is still deeply unprofitable on a GAAP basis, and with the stock near its two-year high and an Opportunity score of just 7/100, much of the launch success already appears priced in. Investors should also weigh the risks inherent to a single-product commercial-stage biotech, including reimbursement, competition, and execution risk on the ongoing ramp. As with all equities, MDGL carries risk of loss; this analysis is based on Yahoo Finance data as of September 10, 2026, which may be delayed or contain errors, and is for informational purposes only, not financial advice – readers should conduct their own due diligence or consult a licensed advisor.